Uriach increases sales by 3% in 2025 and reaches €500M in a year marked by the consolidation of its businesses
The pharmaceutical group expects that inflation and the war in the Middle East will have a negative impact on this year's results
L'Hospitalet de LlobregatUriach reinforces its commitment within the health segment based on natural and self-care products and consolidates its business model in Europe. After a decade marked by a dozen acquisitions across the Old Continent, the Catalan pharmaceutical company closed the year 2025 with a 3% increase in sales, nearing the 500 million euros it had set as a goal when it began its strategic plan in 2015. While the improvement falls short of the figures recorded in the previous year – turnover in 2024 increased by 54% – the company acknowledges that the last year has been characterized by a "complex" context after several years of high-growth markets.
the figures registered in the previous exerciseBeyond the slowdown in both turnover and operating gross profit, Uriach remains watchful of the effects of inflation for the coming year. With price escalation increasingly exacerbated by the conflict in the Middle East, Segarra acknowledges that the effects of the crisis are already beginning to be felt. According to the family group's CEO, it is estimated that inflation, which has affected the purchasing power of its customers, will have a negative impact of at least one million euros on the company's sales this year. Should the war be prolonged, the effect could be even greater, both due to the reduction in real wages and the increased cost of some raw materials used by the company.
However, Segarra also pointed out that both the company and the natural consumer healthcare sector are
"quite resilient" to the effects of the conflict. On the one hand, because sales are mainly concentrated in the European market, thus also avoiding the negative effects of the tariffs promoted by the President of the United States, Donald Trump. And, on the other hand, because a significant part of the raw materials used by Uriach for the manufacture of its products come largely from the European continent.
Evolution of the markets
After betting on the expansion of its business in Europe, the family group closed the year with a presence in twelve European countries. The last acquisition was precisely this 2025, when it incorporated the Greek company i-Pharma, a distributor of Uriach in the country that billed around 1.5 million euros annually.
According to the results presented this Wednesday, the improvement in sales this 2025 is mainly due to the evolution of the markets in Southern Europe –Spain and Portugal– and Southwestern Europe –Italy, Romania, and Greece–, some of which are growing at rates close to double digits. On the other hand, the markets in Central and Northern Europe –including Germany, France, Austria, Switzerland, and the Benelux– have registered a less positive evolution.
Regarding exports, the pharmaceutical company achieved sales of 30 million euros through its three main markets, which are Germany, Spain, and France. As the group has detailed, its products are currently distributed in about eighty countries and Latin America is the most powerful region outside of Europe. A relevant part of foreign sales is also concentrated in the Middle East, followed by Asia, while the United States market continues to be residual.
Pause in acquisitions
In the results presentation this Wednesday, Segarra stated that the group's intention for 2026 remains to consolidate the acquired brands and boost the company's organic growth. In this regard, he pointed out that the company intends to temporarily set aside acquisitions this year, although it does not rule out resuming operations for the next fiscal year.
Along the same lines, the CEO expressed the Uriach family's desire to continue maintaining a majority stake in the company, in which they now control around 70%. "We will continue to use debt and equity as financing methods," indicated Segarra, who also ruled out shareholder changes or stock market listings.
Precisely regarding shareholding, the group's top executive highly valued the entry three years ago of the British fund IGC, which today controls about 30% of the shares. "We believe it is the ideal travel companion for us, because it understands the dynamics of a family business and consolidation. [...] We are very happy and the idea is to continue like this," summarized Segarra.
